000130563 001__ 130563
000130563 005__ 20240126184244.0
000130563 0247_ $$2doi$$a10.1016/j.jcrc.2016.02.003
000130563 0248_ $$2sideral$$a94672
000130563 037__ $$aART-2016-94672
000130563 041__ $$aeng
000130563 100__ $$aLorente,L.
000130563 245__ $$aSeptic patients with mitochondrial DNA haplogroup JT have higher respiratory complex IV activity and survival rate
000130563 260__ $$c2016
000130563 5203_ $$aObjective: The influence of mitochondrial deoxyribonucleic acid (mtDNA) haplogroup or oxidative phosphorylation system (OXPHOS) function on survival of septic patients has been scarcely studied. However, the association between mtDNA haplogroup, OXPHOS capacity at diagnosis of severe sepsis, and survival has been not previously reported, and that was the objective of the present study. Methods: This was a prospective, multicenter, observational study. Blood samples from 198 patients at diagnosis of severe sepsis were analyzed to determine mtDNA haplogroup and platelet respiratory complex IV (CIV) specific activity. The end point of the study was 30-day survival. Results: Septic patients with mtDNA haplogroup JT showed higher 30-day survival than those with mtDNA haplogroup non-JT (31/38 81.6%] vs 99/160 61.9%]; P= .02). Septic patients with mtDNA haplogroup JT showed higher platelet CIV specific activity than those with mtDNA haplogroup non-JT (P= .002). Conclusions: The main novel finding of our study, including the largest series providing data on platelet CIV specific activity according to mtDNA haplogroup in severe septic patients, was that those with mtDNA haplogroup JT showed higher survival and higher platelet CIV specific activity at diagnosis of severe sepsis than patients with mtDNA haplogroup non-JT.
000130563 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000130563 590__ $$a2.648$$b2016
000130563 591__ $$aCRITICAL CARE MEDICINE$$b15 / 33 = 0.455$$c2016$$dQ2$$eT2
000130563 592__ $$a1.26$$b2016
000130563 593__ $$aCritical Care and Intensive Care Medicine$$c2016$$dQ1
000130563 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000130563 700__ $$aMartín,M. M.
000130563 700__ $$0(orcid)0000-0002-3217-1424$$aLópez-Gallardo,E.$$uUniversidad de Zaragoza
000130563 700__ $$aFerreres,J.
000130563 700__ $$aSolé-Violán,J.
000130563 700__ $$0(orcid)0000-0002-3312-9383$$aLabarta,L.$$uUniversidad de Zaragoza
000130563 700__ $$aDíaz,C.
000130563 700__ $$aJiménez,A.
000130563 700__ $$0(orcid)0000-0003-1770-6299$$aMontoya,J.$$uUniversidad de Zaragoza
000130563 700__ $$0(orcid)0000-0002-0269-7337$$aRuiz-Pesini,E.$$uUniversidad de Zaragoza
000130563 7102_ $$11003$$2443$$aUniversidad de Zaragoza$$bDpto. Anatom.Histolog.Humanas$$cArea Histología
000130563 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000130563 7102_ $$11002$$2060$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Bioquímica y Biolog.Mole.
000130563 773__ $$g33 (2016), 95-99$$pJ. crit. care$$tJOURNAL OF CRITICAL CARE$$x0883-9441
000130563 8564_ $$s351336$$uhttps://zaguan.unizar.es/record/130563/files/texto_completo.pdf$$yVersión publicada
000130563 8564_ $$s2786901$$uhttps://zaguan.unizar.es/record/130563/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000130563 909CO $$ooai:zaguan.unizar.es:130563$$particulos$$pdriver
000130563 951__ $$a2024-01-26-18:10:08
000130563 980__ $$aARTICLE